Fig. 2: CD133 is positively correlated with MDR1/P-gp in CRC.
From: Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer
a, b High expression of CD133 correlated with the DOX resistance signalling pathway and the ABC transporter-signalling pathway, as revealed using the TCGA datasets (n = 459). NES, normalised enrichment score. c Kaplan-Meier analysis of overall survival in patients with variable CD133 expression according to the data from the TCGA database (p = 0.036). d Expression of CD133 and P-gp protein was evaluated by IHC in selected CRC tissues (n = 38). e Kaplan-Meier analysis of overall survival in patients with variable CD133 expression according to data from selected CRC specimens (p = 0.032). f, g Expression levels of CD133 and P-gp are positively correlated among all the tissue samples. h Comparison of MDR1 mRNA expression levels in selected CRC specimens (n = 38). i, j Expression levels of CD133 and MDR1 mRNA are positively correlated among all the tissue samples (n = 38).
